• Milton Safenowitz Postdoctoral Fellowship Program (2022)

    Registration Now Open
    Letter of Intent due March 8, 2022

    The ALS Association’s Milton Safenowitz Postdoctoral fellowship grant program supports the development of new scientists in the field of ALS by funding junior postdoctoral fellows doing research of high scientific merit and relevance to amyotrophic lateral sclerosis (ALS).

    Overview

    The ALS Association Global Research Program leads the scientific community in finding effective treatments and cure for ALS, and a better life for people with ALS, their caregivers, and families. The ALS Association is the largest philanthropic funder of ALS research worldwide, and our efforts have led to some of the most promising and significant advances in ALS research.

    The ALS Association is proud to support the development of new scientists through the Milton Safenowitz Postdoctoral Fellowship. The Safenowitz family, through The Greater New York Chapter of The ALS Association, founded the award in memory of Mr. Safenowitz, who died of ALS in 1998. These awards are to encourage and facilitate promising young scientists to enter the ALS field. Fellows work with a senior mentor and receive extensive exposure to the ALS research community through meetings and presentations. After completing this fellowship, over 75 percent of the awardees stay in ALS research. They go on to establish their own laboratories to continue studying ALS and mentor more ALS researchers along the way. Other postdoctoral fellows have moved on to successful careers in industry, medical writing, and non-profit organizations.

    To view the full funding announcement, click here

    Topics of Interest (Scope)

    We are especially interested in Fellowships supporting the following:

    • Studies for new target validation including in animal models, and human cell models.
    • Studies that would elucidate target or pathway biology in disease-relevant models, including defining upstream/downstream modifiers and convergence of promising target pathways.
    • Studies of risk factors that could ultimately reduce the risk of developing ALS including studies of genetic risk factors, epigenetics, gene-environment interactions, lifestyle, occupational or dietary factors and epidemiology.
    • Studies of new biomarker identification, and development and/or validation of biomarker assays.
    • Studies to help people living with ALS, including development and/or validation of novel assistive technology and measurement of patient/caregiver/family burden.
    • Studies employing analysis of omics data for purposes such as identification of disease-relevant patient subtypes, new therapeutic targets or new biomarkers. Data analyzed could come from resources including, but not limited to, PRO-ACT, Project MinE or Answer ALS.

    PLEASE NOTE: Priority will be given to specific biological targets and areas of research not previously funded through this program in the last three years. Proposals with significant overlap to already funded work will likely not be considered. To view the previous fellowships awarded through this program, please visit The ALS Association’s Milton Safenowitz Postdoctoral Fellowship Program section on our website. 

    Funding and Eligibility

    Budgets for total direct costs up to $75,000 per year may be requested ($150,000 total direct costs for two years of support). Indirect costs are not provided for postdoctoral fellowship awards. Individuals who have the skills, knowledge, and resources necessary to carry out the proposed research and have an existing postdoctoral fellowship, including the support of their mentor. Applicants who received their highest degree (e.g. PhD or MD) less than three years before the date the award starts are eligible to apply. 

    Deadlines

    • Letter of Intent Due Date: March 8, 2022 5 p.m. US ET
    • Full Application Due Date (by invite only): May 10, 2022, 5 p.m. US ET
    • Anticipated Award Decision: July 2022
    • Anticipated Earliest Start Date: July 2022

    Online Submission

    To Register for a proposalCENTRAL account, create a new Letter of Intent or to access an existing saved Letter of Intent, please visit: https://proposalcentral.com/

    Questions

    We encourage inquiries concerning this funding opportunity and welcome the opportunity to answer questions from potential applicants. Submit general questions and other related correspondence to researchgrants@alsa-national.org.

  • ALS Scholars in Therapeutics

    Due date for nominations is April 29, 2022

    The Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital (MGH) in partnership with ALS Finding a Cure® (ALSFAC) and FightMND is issuing a request for applications for the ALS Scholars in Therapeutics Program to empower young investigators to learn how to develop new treatments for people living with ALS. Full announcement can be found here.

    This two-year program is designed to engage clinician-scientists and post-doctoral fellows to gain training and experience in therapy development for ALS at their home institution with an optional industry experience in year two. All ALS Scholars will be part of the broader ALS global community. We believe strongly in identifying, supporting, and mentoring the next generation of researchers and are continuing this tradition through the ALS Scholars in Therapeutics Program. 

    Award Details

    • 2 years of funding to support a clinician-scientist or post-doctoral fellow working in the ALS field anywhere in the world.
    • $150,000 award/funding year
    • Recipient must commit at least 75% effort to the proposed ALS research plan

    Eligibility

    • Applications from clinician scientists and postdoctoral fellows focused on translational research.
    • Candidates with Ph.D. or M.D. with strong publication record. International applicants are encouraged to apply.
    • The ALS focused proposal must have a strong scientific rationale and should be largely developed by the fellow with guidance from his/her mentor.
    • Eligibility for this award is based on the date the candidate attained their degree/qualification. For MDs, scholars will be considered if they have completed their specialist qualification (i.e., US Residency; Fellowship of the Royal Australasian College of Physicians, etc.) For PhDs, they can be no more than 5 years post-degree.

    Application Due Dates:

    Release of RFA: March 2, 2022

    Applications Due: April 29, 2022

    Notification of Award: June 2022

    Initiation of Award*: July 1, 2022 (flexible once contracts signed)

    For queries contact: HealeyCenterforALS@mgh.harvard.edu

    To download an application form: click here

    Submit Application as a single PDF document to HealeyCenterforALS@mgh.harvard.edu

  • Clinical Trial Awards Funding Program

    The ALS Association is proud to announce a new grant funding opportunity through the Clinical Trial Awards (CTA) program. Letters of Intent are due on April 21, 2022 (5 pm US ET).

    The CTA program provides support for early-stage interventional clinical trials to discover new treatments and cures for ALS. Type of clinical trials supported through this program are early to mid-phase (phase 1, phase 2a) exploring safety or biomarkers to justify larger phase 2b studies (such as the Healey platform trial platform). The program is open to industry and academic investigators and includes development of pharmacological treatments, biological therapies, or gene therapies. Successful applicants will receive up to $1,000,000 in funding over three years.

    For more details see: https://www.als.org/research/funding-opportunities

    For questions, please contact us at researchgrants@alsa-national.org. We look forward to your proposals.

  • Fiscal Year 2022 (FY22) Department of Defense (DOD) Funding Opportunities

    Fiscal Year 2022 (FY22) funding opportunities for the Department of Defense (DOD) Amyotrophic Lateral Sclerosis Research Program (ALSRP) managed by the Congressionally Directed Medical Research Programs (CDMRP)

    FY22 Funding Opportunities released:

    AMYOTROPHIC LATERAL SCLEROSIS RESEARCH PROGRAM (ALSRP) at https://cdmrp.army.mil/funding/alsrp

    • Pilot Clinical Trial Award
    • Clinical Biomarker Development Award
    • Therapeutic Idea Award
    • Therapeutic Development Award

    A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Funding Opportunities/Program Announcements and General Application Instructions which can be found on the Grants.gov website (https://Grants.gov).  A listing of all CDMRP and other USAMRDC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using Assistance Listing (formerly CFDA) Number 12.420.

    New for FY22: The applicant organization must be registered as an entity in SAM (https://www.sam.gov/SAM/) and receive confirmation of an “Active” status before submitting an application through Grants.gov.  As published in the Federal Register 10 July 2019 (https://www.federalregister.gov/documents/2019/07/10/2019-14665/unique-entity-id-standard-for-awards-management), the Unique Entity Identifier for awards management generated through SAM will replace the Data Universal Numbering System (DUNS) number as of April 2022. CDMRP has transitioned to use of the Unique Entity Identifier (SAM) and will utilize the latest SF 424 which includes the UEI. The DUNS will no longer be accepted.

    For email notification when CDMRP funding opportunities are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org. For more information about the CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).

    For more information on types of funding opportunities offered and application strategies review the CDMRP Webinar Series: https://cdmrp.army.mil/pubs/Webinars/webinar_series.

  • Gupta Family Endowed Prize for Innovation in ALS Care

    Due date for nominations is May 27, 2022

    The Gupta Family Endowed Prize for Innovation in ALS Care is an annual global prize to honor ground-breaking new approaches that lead to exceptional care for individuals living with amyotrophic lateral sclerosis (ALS). The goal of this prize is to encourage idea sharing, innovation, and forward-thinking on scalable ongoing and ground-breaking projects that have directly improved ALS patient care. This annual prize is awarded to a nominated team who has developed promising new approaches to improving care for people living with ALS.

    The Gupta Family Endowed Prize was established in 2021 at the Sean M. Healey & AMG Center for ALS at Mass General under the direction of Merit Cudkowicz, MD, MSc, Chief of Neurology at Mass General. Learn more about the 2021 prize winners here.

    Prize Criteria

    There are no limits on the types of solutions to improve care. Examples of ALS care innovation include but are not limited to assistive technology, multidisciplinary care, communication and education, trials, nutrition.

    • The project nominated should be realized and ongoing as well as scalable to reach a larger group of people living with ALS within 1 year.
    • Nominees should have a touchpoint with patients and/or caregivers.
    • Nominations are accepted from all but preference will be given to projects led by junior investigators/teams/clinicians.
    • Nominations do not have to be from an academic institution.
    • We strongly discourage multiple nominations for the same team as one will suffice.
    • While self-nominations are allowed, nominations by others are preferred. 

    Selection

    The awardees will be selected by members of the Gupta family, Healey Center Scientific Advisory Council, NEALS PEACe Committee and advisors who are living with ALS.

    Timeline for Submission

    Release Date: April 13, 2022

    Nomination Due Date: May 27, 2022

    Notification to successful candidate: June 2022

    Presentation of award: 21st Annual NEALS Meeting November 1 - 3, 2022

    Download Nomination form here

    Submit completed nomination form and supporting documents as a single PDF to healeycenterforals@mgh.harvard.edu

    Award: $20,000 USD and travel reimbursement up to $2,500 USD to attend Annual NEALS Meeting

    To learn more about the Sean M. Healey and AMG Center for ALS click here

  • Neuromuscular Faculty for Rutgers-Robert Wood Johnson Medical School, Department of Neurology

    The Department of Neurology at Rutgers Robert Wood Johnson (RWJ) Medical School is seeking a full-time faculty member with interest in Neuromuscular Disorders.  Candidates must be graduates of an ACGME accredited neurology residency, are board certified and have strong interests in clinical research and teaching.

    The Robert Wood Johnson Medical School, Department of Neurology is part of Rutgers University in New Brunswick/Piscataway and is affiliated with the Robert Wood Johnson University Hospital, the primary teaching hospital for Rutgers RWJ Medical School. The Department of Neurology at Rutgers-RWJ Medical School is an academic department with more than 30 full time faculty and 5 nationally recognized centers of excellence.

    Rutgers, The State University of New Jersey, is an Affirmative Action/Equal Opportunity Employer, M/F/D/V and a member of the State University Health System of NJ.  Rutgers, The State University of New Jersey, does not discriminate on the basis of race, color, national origin, sex, sexual orientation, gender identity or expression, disability, age, or any other category covered by law in its admission, programs, activities, or employment matters.

    For further information on the notice of nondiscrimination, you may contact the U.S. Department of Education, Office for Civil Rights, at 646-428-3900 or OCR.NewYork@ed.gov

    Women and minorities are strongly encouraged to apply.

    Duties Description & Apply Online: https://jobs.rutgers.edu/postings/131671

    For consideration, please send a letter of interest and CV to:

    Suhayl Dhib-Jalbut, MD
    Professor & Chairman of Neurology
    Ruth Dunietz Kushner and Michael Jay Serwitz Chair in Multiple Sclerosis
    Rutgers-New Jersey Medical School & Robert Wood Johnson Medical School

    Mailing: Department of Neurology, 125 Paterson St. Ste. 6200
    New Brunswick, NJ 08901 Email: jalbutsu@rutgers.edu

  • Neuromuscular Division Chief for Rutgers-Robert Wood Johnson Medical School, Department of Neurology

    The Department of Neurology at Rutgers Robert Wood Johnson (RWJ) Medical School is seeking a full-time faculty member to serve as Division Chief of Neuromuscular Disorders.  Candidates must be graduates of an ACGME accredited neurology residency, are board certified and have strong interests in clinical research and teaching.  Candidate must have fellowship training in Neuromuscular Disorders and electromyography with academic and administrative experience. Academic rank will be consistent with qualifications and experience.  He/she will supervise division faculty, fellows, nurse practitioners and research assistants, oversee clinical care delivered by division faculty, and promotes investigator-initiated scholarship by division members.  Candidate will also oversee the MDA-designated ALS Center of Excellence. Candidate will report to the Chairman of the Department of Neurology.

    The Robert Wood Johnson Medical School, Department of Neurology is part of Rutgers University in New Brunswick/Piscataway and is affiliated with the Robert Wood Johnson University Hospital, the primary teaching hospital for Rutgers RWJ Medical School. The Department of Neurology at Rutgers-RWJ Medical School is an academic department with more than 30 full time faculty and 5 nationally recognized centers of excellence.

    Rutgers, The State University of New Jersey, is an Affirmative Action/Equal Opportunity Employer, M/F/D/V and a member of the State University Health System of NJ.  Rutgers, The State University of New Jersey, does not discriminate on the basis of race, color, national origin, sex, sexual orientation, gender identity or expression, disability, age, or any other category covered by law in its admission, programs, activities, or employment matters.

    For further information on the notice of nondiscrimination, you may contact the U.S. Department of Education, Office for Civil Rights, at 646-428-3900 or OCR.NewYork@ed.gov

    Women and minorities are strongly encouraged to apply.

    Apply Online: https://jobs.rutgers.edu/postings/125703

    For consideration, please send a letter of interest and CV to:

    Suhayl Dhib-Jalbut, MD
    Professor & Chairman of Neurology
    Ruth Dunietz Kushner and Michael Jay Serwitz Chair in Multiple Sclerosis
    Rutgers-New Jersey Medical School & Robert Wood Johnson Medical School

    Mailing: Department of Neurology, 125 Paterson St. Ste. 6200
    New Brunswick, NJ 08901 Email: jalbutsu@rutgers.edu

  • Lab Research Coordinator (FT), Neurology

    Serve as research coordinator for a collaborative research group seeking to identify environmental and genetic factors that contribute to the neurodegenerative disease, amyotrophic lateral sclerosis (ALS). Will perform a wide range of tasks associated with supporting pre-clinical ALS research, while managing multiple research activities and analyses. Research activities include processing and analysis of human samples as well as management of subject data and specimens collected for the team’s biorepository and epidemiological questionnaire and registry databases.

    Learn More

  • Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)

    Letter of Intent Due Date: May 17, 2022

    Applications Due: June 17, 2022

    As authorized by the Accelerating Access to Critical Therapies for ALS Act (P.L. 117-79), this FOA will support highly meritorious research utilizing data from expanded access to investigational drugs and biological products for individuals who are otherwise not eligible for ALS clinical trials. Such research may bring new insight into ALS biomarkers, progression of the disease over time, and information about the experience of people taking such an agent.

    Grants are available to phase 3 clinical trial sites sponsored by small businesses testing investigational drugs or biologic products for ALS. Organizations will need to have received authorization for an expanded access IND from the FDA before a grant application can be reviewed, and all applications will go through NIH peer review.  

    Learn More

  • Target ALS Foundation Invites Proposals for ALS Biology-Focused Collaborative Projects

    Target ALS is inviting inviting letters of intent for collaborative projects with a deadline of Friday, July 15, 2022. As with all Target ALS Foundation calls, only collaborative projects will be funded. Collaborative projects for this call comprise groups of 3-5 laboratories working around a common research theme or target. Inclusion of investigators with less than five years’ experience running an independent laboratory or new to the field of ALS is encouraged. Download the full invitation for details.

  • Healey Center International Prize for Innovation in ALS

    Due date for nominations is July 22, 2022

    The last decade has seen unprecedented advances in our understanding of the biology of the disease, an exponential increase in novel targets and innovative approaches to developing therapies. The 4th annual Healey Center International Prize for Innovation in ALS is a global prize celebrating excellence in research for a team of investigators who catalyse exceptional discoveries leading to a transformative advance in therapy development in ALS.

    Sean M. Healey, executive chairman of Affiliated Managers Group, Inc. (AMG) joined AMG when it was a start-up in 1995 and together with his founding colleagues built the firm into one of the largest global asset management companies with over $830 billion under management – AMG is NYSE-listed and a component of the S&P 500. Prior to AMG, Sean began his career as an investment banker in the Mergers and Acquisitions Department at Goldman Sachs.

    Mr. Healey was diagnosed with ALS in May 2018. Following his diagnosis, he took a step back from his long-time role of Chairman and CEO at AMG to aggressively pursue treatment at the guidance of his doctor, Merit Cudkowicz, MD, MSc, Chief of Neurology at Mass General. Together, with his company and friends, he established the Sean M. Healey & AMG Center for ALS at Mass General.

    Prize Criteria

    Team of investigators who made a significant advance in the ALS field impacting the development of novel therapies for ALS, including, but not limited to the following:

    • A technology to identify novel targets for drug development
    • A technology to advance therapy development for ALS
    • Tools or targets to stratify the ALS population and improve clinical trial design
    • A global, multiple disciplinary collaboration that leads to new insights into the biology of the disease and translates into novel approaches for therapy development
    • A novel outcome measure to improve efficiency in clinical trials in patients with ALS

    Timeline for Submission

    Release Date: May 25, 2022
    Nomination Due Date: July 22, 2022
    Notification to successful candidate: September 2022
    Presentation of award: Virtual 33rd International Symposium on ALS/MND December 2022

    Download Nomination form here

    Submit completed nomination form and supporting documents as a single PDF to healeycenterforals@mgh.harvard.edu

    Award: $50,000 USD

    To learn more about the Annual Healey International Prize for Innovation in ALS recipients click here

    To learn more about the Sean M. Healey and AMG Center for ALS click here

     

  • Trial Capacity Awards (2022)

    Letter of Intent due June 29, 2022

    The ALS Association’s Trial Capacity Awards support efforts to increase participation in ALS clinical trials and efforts to improve the speed and efficiency of clinical trial conduct at both established and emerging ALS clinical trial sites.

    Overview

    The ALS Association has established a goal to significantly increase the number of high-quality clinical trials in the ALS ecosystem as part of its strategic priority to find new treatments and cures. There is an urgent need to increase the number and capacity of trial sites to complement this increase in the number of trials. Increases in clinical trial capacity will allow for potential new therapies to be tested faster and will improve trial accessibility for people with ALS in currently underserved areas. The Clinical Trial Capacity Awards will support efforts to increase the number and diversity of people living with ALS who have the opportunity to participate in clinical trials, and efforts to improve the speed and efficiency of clinical trial conduct at both established and emerging clinical trial sites across the US. 

    Many people living with ALS want to participate in clinical trials but are currently either unaware of opportunities or unable to engage in them due to lack of accessibility to clinical trial sites within their local areas. These awards should help eliminate barriers, especially those impacting currently underserved populations, to trial participation. Similarly, many ALS clinics and drug development companies wish to pursue clinical development in ALS and these awards should help establish infrastructure allowing them to conduct faster and more efficient clinical trials in ALS. Applications that focus primarily on specific barriers / bottlenecks rather than spreading funding across all trial-related expenses are preferred. 

    To view the full funding announcement, click here

    Topics of Interest (Scope)

    Examples of items that this funding opportunity will support include:

    • Salary support for study personnel, including but not limited to support for: clinical trial coordinators, research project or program managers, research assistants, regulatory specialists, physicians and allied health providers, budget/contracting and other administrative support, etc.
    • Physical infrastructure, including but not limited to: lab equipment and space, biosample handling and storage (e.g., freezers, centrifuge) equipment for outcome measures (spirometry, hand held dynamometry, etc.), etc.
    • Efforts to increase trial recruitment and retention in underserved populations, including but not limited to funding of: patient travel costs, language translation services, telehealth utilization, local community partnerships for targeted outreach, etc.
    • Training and associated costs specific to the conduct of ALS trials, such as registration costs or travel costs for attendance to NEALS trainings, licensing, professional memberships and certifications.
    • Services specific to the conduct of ALS trials such as: genetic testing and counseling, required hospital services, specialized contract support staff, pharmacy contracting for drug supply, start-up support, etc.
    • Note that grant support should not be used for services for a specific clinical trial but rather for building capacity that is applicable for multiple trials
    • Cross-site or cross-disease coordination efforts to improve availability of trials and services to patients (e.g., coordination with other neurodegenerative diseases, leveraging with other trial sites in the local area to share trial participants or travel funds to support experienced study personnel from established trial sites providing mentorship/training at emerging trial sites).
    • Other efforts to improve efficiency and effectiveness of clinical trial recruitment and retention.
    • The following are not appropriate for this funding opportunity: Support for individual research projects or clinical trials, Support for clinical care, Any costs, including those listed as in scope examples above, that are already covered by a clinical trial sponsor

    Funding and Eligibility

    • The maximum period of performance is four years
    • The maximum total budget is $400,000 (inclusive of both direct and indirect costs)
    • Indirect costs are limited to 10 percent of the total direct costs   
    • All funds must be expended within the approved period of performance

    Deadlines

    • Letter of Intent Due Date: June 29, 2022, 5 p.m. US ET
    • Full Proposal Due Date (by invite only): August 31, 2022, 5 p.m. US ET
    • Anticipated Award Decision: October 2022
    • Anticipated Earliest Start Date: November 2022

    Online Submission

    To Register for a proposalCENTRAL account, create a new Letter of Intent or to access an existing saved Letter of Intent, please visit: https://proposalcentral.com/

    Questions

    We encourage inquiries concerning this funding opportunity and welcome the opportunity to answer questions from potential applicants. Submit general questions and other related correspondence to researchgrants@alsa-national.org.

  • MDA Venture Philanthropy

    MDA Venture Philanthropy

    MDA Venture Philanthropy (MVP) is the Muscular Dystrophy Association's drug development program, which operates within MDA's Translational Research program. MVP is exclusively focused on funding the discovery and clinical application of treatments and cures for neuromuscular diseases.

    Adapting elements of the venture capital model, the MVP business plan is characterized by an emphasis on measurable results along with deep involvement by its scientific and industry advisers. MVP evaluates and makes targeted investments in for-profit and not-for-profit companies and academics developing therapeutics for neuromuscular diseases.

    Building upon MDA's long-term investment in research and health care, MVP is designed to complement MDA's ongoing programs of health care, lifesaving services, advocacy, basic and clinical research, and professional and public health information. MVP also benefits from MDA's other research programs that support basic research, clinical trials and research infrastructure.

    Business Plan

    A strategy for lowering barriers to therapeutic development: MVP leverages MDA's years of expertise in research into nerve and muscle biology to create a unique environment to foster translation of research into therapies. Dedicated staff scientists track research developments from MDA's basic research program and from the scientific community as a whole and match the most promising ideas with drug development companies capable of developing such therapies. Where companies have promising therapeutics, MVP helps match the company with disease experts to expedite and streamline development. Where academic projects need more data before they will be attractive to a corporate partner, MVP helps match the researcher with experts in drug development. As a "partner" and not just a funder, MVP will help to cultivate follow-on investors, while its access to patients, experts and research infrastructure can offset some costs of drug development.  

    Bridging the high-risk stages of therapy development: MVP makes targeted investments in projects for which the therapeutic of interest is unlikely to advance via traditional funding avenues due to the perceived risk of a small market, lack of a clear regulatory path or new technology. MVP funds are leveraged to aid getting projects through the critical stages of development to ensure that successful therapies attract funding from other sources and get to market. Co-investors and follow-on funders with complementary skills are cultivated actively in the form of venture capital groups, other nonprofits, and larger biotechnology and pharmaceutical companies. Exit points for MVP funding may include the situations in which 1) a therapeutic progresses to phase III or is approved; or 2) significant funding from follow-on investor(s) is received. Return on investment strategies for MVP may include revenue sharing from licensing agreements or commercialization of the therapeutic, or less commonly, sales of preferred stock.

    MVP uses elements of the venture capital model: MVP uses an iterative evaluation process that reviews the science, management, financials, legal issues and intellectual property of the company or project. MVP holds monthly teleconferences open to its advisers at which decisions to advance projects to the next stage of evaluation are made. In addition to the diverse qualifications of MVP's program staff, advisory committees and ad hoc scientific experts, MVP may utilize well-established outside contractors for formal financial and legal diligence. MVP manages its grants as if they were investments such that funding commitments are structured as milestone-driven contracts.

    A unique blend of staff, contractors and volunteers: MVP has access to a unique set of expertise that it uses to select projects to invest in and to manage those projects. The scientific advisers consist of experts in neuromuscular disease research, neuromuscular medicine, biotechnology venture capital investment and drug development. MVP staff scientists work with these volunteers to select projects with the best possible chance of success, and to act as advisers as those projects move forward. MVP uses its business advisers and outside contractors for legal and financial diligence and for contract negotiation, ensuring that MVP invests only in projects likely to have the greatest possible impact. The business advisers are volunteers with expertise in mergers and acquisitions, biotechnology investing, investment banking and corporate development.

    For information on how to apply to the MDA Venture Philanthropy program, please visit Funding Opportunities and click on MVP.